Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

A research team from Osaka University investigates the impact of antioxidant enzymes on specific cell types and their role in ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

The distinct population of endothelial cells that line blood vessels in the insulin-producing "islets" of the human pancreas ...

A team from Osaka University has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

The full research findings are available in Blood (Volume 145, Number 3, 334-347, January 16, 2025).